MarketCap
Facebook
X
TelegramAnnual report 2025
added 02-24-2026
Gilead Sciences Total Assets 2011-2026 | GILD
Total Assets — these are all the resources owned by the business that have economic value. They are used to operate the business, generate profit, and ensure the company’s stability.Main categories of assets
Current assets (used within one year):
- Cash and cash equivalents
- Accounts receivable (amounts owed by customers)
- Inventory of goods, raw materials, and supplies
- Short-term investments
- Fixed assets (buildings, machinery, equipment)
- Intangible assets (brands, patents, software)
- Long-term investments
- Goodwill (reputational value from mergers)
Assets represent an objective measure of a business's value, reflecting everything behind it: physical infrastructure, technology, customer base, and financial resources. A high share of liquid assets such as cash indicates a company’s financial flexibility and its ability to maintain stability in changing market conditions.
Asset analysis helps assess how effectively a company utilizes its resources to generate revenue and profit, reflecting its operational efficiency and ability to convert invested capital into financial results.
Annual Total Assets Gilead Sciences
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 59 B | 59 B | 62.1 B | 63.2 B | 68 B | 68.4 B | 61.6 B | 63.7 B | 70.3 B | 57 B | 51.8 B | 34.7 B | 22.5 B | 21.2 B | 17.3 B |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 70.3 B | 17.3 B | 52 B |
Quarterly Total Assets Gilead Sciences
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 58.5 B | 55.7 B | 56.4 B | 59 B | 54.5 B | 53.6 B | 56.3 B | 62.1 B | 62.4 B | 62.3 B | 61.9 B | 63.2 B | 62.6 B | 62.9 B | 63.1 B | 68 B | 67.1 B | 68 B | 67.5 B | 68.4 B | 68.4 B | 68.4 B | 68.4 B | 61.6 B | 61.6 B | 61.6 B | 61.6 B | 63.7 B | 63.7 B | 63.7 B | 63.7 B | 70.3 B | 70.3 B | 70.3 B | 70.3 B | 57 B | 57 B | 57 B | 57 B | 51.7 B | 51.7 B | 51.7 B | 51.7 B | 34.7 B | 34.7 B | 34.7 B | 34.7 B | 22.6 B | 22.5 B | 22.5 B | 22.5 B | 21.2 B | 21.2 B | 21.2 B | 21.2 B | 17.3 B | 17.3 B | 17.3 B | 17.3 B |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 70.3 B | 17.3 B | 51.5 B |
Total Assets of other stocks in the Biotechnology industry
| Issuer | Total Assets | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
2.03 B | - | 2.43 % | $ 254 M |  Germany |
 |
I-Mab
IMAB
|
6.33 B | - | - | $ 866 M |  China |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
18.1 B | - | - | $ 40.3 B |  USA |
 |
Genfit SA
GNFT
|
151 M | - | 2.54 % | $ 160 B |  France |
 |
Autolus Therapeutics plc
AUTL
|
589 M | $ 1.36 | -2.52 % | $ 362 M |  Britain |
 |
Biophytis SA
BPTS
|
12 M | - | -13.47 % | $ 169 M | France |
 |
Midatech Pharma plc
MTP
|
14.8 M | - | -18.52 % | $ 27.3 M | Britain |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
15.2 M | - | -1.52 % | $ 24.7 M | USA |
 |
Acorda Therapeutics
ACOR
|
109 M | - | -24.86 % | $ 820 K | USA |
 |
DBV Technologies S.A.
DBVT
|
234 M | $ 20.25 | -0.54 % | $ 2.83 B | France |
 |
Dyadic International
DYAI
|
9.95 M | $ 0.87 | 0.59 % | $ 31.5 M | USA |
 |
Alterity Therapeutics Limited
ATHE
|
41.4 M | $ 3.78 | 4.83 % | $ 9.09 B |  Australia |
 |
Advaxis
ADXS
|
16.6 M | - | -9.65 % | $ 45.9 M | USA |
 |
Adverum Biotechnologies
ADVM
|
180 M | - | - | $ 86.2 M | USA |
 |
Aytu BioScience
AYTU
|
124 M | $ 2.6 | -2.26 % | $ 16.3 M | USA |
 |
Институт стволовых клеток человека
ISKJ
|
1.51 B | - | - | - |  Russia |
 |
Fate Therapeutics
FATE
|
319 M | $ 1.14 | -4.2 % | $ 135 M | USA |
 |
Forte Biosciences
FBRX
|
82.8 M | $ 26.44 | - | $ 342 M | USA |
 |
Aeterna Zentaris
AEZS
|
35.1 M | - | 5.93 % | $ 314 M |  Canada |
 |
Fennec Pharmaceuticals
FENC
|
70.6 M | $ 6.16 | -4.05 % | $ 176 M | USA |
 |
AgeX Therapeutics
AGE
|
6.95 M | - | -10.17 % | $ 12.2 K | USA |
 |
Aeglea BioTherapeutics
AGLE
|
778 M | - | - | $ 1.01 B | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
66.7 M | - | - | $ 26.5 M | USA |
 |
Amicus Therapeutics
FOLD
|
950 M | $ 14.46 | 0.03 % | $ 4.46 B | USA |
 |
AIkido Pharma
AIKI
|
113 M | - | 1.93 % | $ 17.4 M | USA |
 |
Fulcrum Therapeutics
FULC
|
366 M | $ 7.57 | -3.32 % | $ 480 K | USA |
 |
Aptose Biosciences
APTO
|
10 M | - | -45.71 % | $ 1.2 M | Canada |
 |
Galectin Therapeutics
GALT
|
19.5 M | $ 2.28 | -11.13 % | $ 146 M | USA |
 |
Galmed Pharmaceuticals Ltd.
GLMD
|
18.5 M | $ 0.54 | 4.28 % | $ 503 K |  Israel |
 |
Akero Therapeutics
AKRO
|
826 M | - | - | $ 3.67 B | USA |
 |
Genmab A/S
GMAB
|
21.1 B | $ 27.14 | -2.2 % | $ 17 B |  Danmark |
 |
CureVac N.V.
CVAC
|
1.16 B | - | - | $ 867 M | Germany |
 |
BioNTech SE
BNTX
|
22 B | $ 88.2 | -3.37 % | $ 27.2 B | Germany |
 |
Gossamer Bio
GOSS
|
172 M | $ 0.32 | -7.11 % | $ 73.1 M | USA |
 |
Coherus BioSciences
CHRS
|
258 M | $ 1.62 | -3.29 % | $ 190 M | USA |
 |
Grifols, S.A.
GRFS
|
21.4 B | $ 7.98 | -3.04 % | $ 6.83 B |  Spain |
 |
Akari Therapeutics, Plc
AKTX
|
47.9 M | $ 3.5 | -1.13 % | $ 236 B | Britain |
 |
Akouos
AKUS
|
279 M | - | 0.23 % | $ 488 M | USA |
 |
GT Biopharma
GTBP
|
8.11 M | $ 0.41 | -8.56 % | $ 2.26 M | USA |
 |
Allakos
ALLK
|
244 M | - | - | $ 28.6 M | USA |
 |
Allena Pharmaceuticals
ALNA
|
34.8 M | - | 3.16 % | $ 1.9 M | USA |
 |
Alnylam Pharmaceuticals
ALNY
|
4.97 B | $ 316.69 | -4.13 % | $ 41.5 B | USA |
 |
Halozyme Therapeutics
HALO
|
2.53 B | $ 63.72 | 1.01 % | $ 7.64 B | USA |
 |
Alpine Immune Sciences
ALPN
|
287 M | - | - | $ 2.17 B | USA |
 |
Aileron Therapeutics
ALRN
|
24.2 M | - | 10.36 % | $ 9.8 M | USA |
 |
AlloVir
ALVR
|
122 M | - | 4.14 % | $ 49.1 M | USA |
 |
Harmony Biosciences Holdings
HRMY
|
1.27 B | $ 27.53 | -0.67 % | $ 1.58 B | USA |
 |
Burford Capital Limited
BUR
|
3.11 B | $ 4.53 | 1.0 % | $ 726 M | Britain |
 |
Atreca
BCEL
|
155 M | - | -11.76 % | $ 5.79 M | USA |